Actively Recruiting
Long-term Safety and Efficacy of Sacral Nerve Stimulation in Patients With Ulcerative Colitis
Led by Xijing Hospital · Updated on 2025-08-11
15
Participants Needed
1
Research Sites
382 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although the incidence of inflammatory bowel disease is stable in North American and European countries, the incidence of inflammatory bowel disease is increasing in newly industrialized countries, especially in China. The treatment drugs for ulcerative colitis include 5-aminosalicylic acid (5-ASA), glucocorticoids, immunosuppressants, and biological agents. The aim of this clinical trial is to evaluate the long-term safety and efficacy of sacral nerve stimulation in patients with ulcerative colitis
CONDITIONS
Official Title
Long-term Safety and Efficacy of Sacral Nerve Stimulation in Patients With Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years
- Diagnosis of ulcerative colitis for at least 3 months
- Mayo score between 6 and 12 and Mayo endoscopic score of 2 to 3 points
- Ulcerative colitis resistant to medical treatment
You will not qualify if you...
- Treatment-naive ulcerative colitis (no previous treatment)
- Acute severe ulcerative colitis
- Currently taking any biological treatments
- Previous surgical treatment or severe colitis with imminent risk of surgery
- Infective colitis
- Other systemic diseases
- Pregnancy and lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xijing Hospital
Xi'an, Shaanxi, China, 710032
Actively Recruiting
Research Team
J
Jian Wan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here